BOSTON – June 20, 2018 – David J. Dykeman and Dr. Fang Xie, patent attorneys and shareholders in the Boston office of global law firm Greenberg Traurig, LLP, were recognized as two of the world’s top intellectual property (IP) value creators in the 2018 edition of the Intellectual Asset Management’s (IAM) Strategy 300 – The World’s Leading IP Strategists 2018. This is Dr. Xie’s third year and Dykeman’s first year of recognition.
According to the publication, the guide identifies the top patent professionals in key jurisdictions around the globe. The patent professionals are identified after a 5-month, extensive research process. IAM conducts nearly 1,500 interviews with attorneys, patent attorneys, and in-house counsel. Recognized patent professionals have received sufficient positive feedback from peers and clients.
Dykeman is co-chair of Greenberg Traurig’s global Life Sciences & Medical Technology Group and the Intellectual Property (IP) Group in Boston. He has over 20 years of experience in patents, IP, and licensing, and focuses his practice on securing strategic worldwide IP protection and related business strategy for high-tech clients, with particular experience in life sciences, medical devices, biotechnology and healthcare IT. Dykeman is the founding co-chair of the American Bar Association’s (ABA) Medical Devices Committee and served on the Editorial Advisory Board of Medical Device + Diagnostic Industry (MD+DI) magazine. An accomplished author and a speaker on medical devices and life sciences IP, Dykeman was honored as a “Life Science Star” by LMG Life Sciences, and was named one of the Top 250 Patent and Technology Licensing Practitioners in the world by IAM magazine.
Dr. Xie focuses her practice on establishing, defending, licensing, sharing and monetizing intellectual property rights for life sciences companies. She has broad experience in worldwide patent portfolio development, intellectual property due diligence, licensing and technology transfer, patentability and product clearance studies, validity/invalidity analyses, patent infringement evaluations, as well as intellectual property litigation and pre-litigation counseling. Her primary technical areas include biotechnology, synthetic biology and pharmaceuticals, with a focus on immunotherapy, antibody and biologics/biosimilars, nucleic acid synthesis, gene editing, protein and organism engineering, stem cell technology, biomarkers, diagnostics, small molecule drugs, regenerative medicine, analytical chemistry and cosmetics.
About Greenberg Traurig’s Intellectual Property & Technology Practice
With more than 180 intellectual property attorneys and agents in the United States, Asia, and Europe, Greenberg Traurig provides a broad range of patent, trademark and copyright protection and strategic counseling. Greenberg Traurig was named a “National Tier 1” Law Firm for IP Litigation, Patent Law, Trademark and Information Technology Law by U.S. News and Best Lawyers, 2017 “Best Law Firms Rankings.”
About Greenberg Traurig’s Boston Office
Established in 1999, Greenberg Traurig’s Boston office is home to over 70 attorneys practicing in the areas of bankruptcy, corporate, emerging technology, energy, governmental affairs, intellectual property, labor and employment, life sciences and medical technology, litigation, public finance, and real estate. An important contributor to the firm's international platform, the Boston office includes a team of nationally recognized attorneys with both public and private sector experience. The team offers clients the value of decades of legal experience and hands-on knowledge of the local business community, supported by the firm's vast network of global resources.
About Greenberg Traurig, LLP
Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2017 Am Law Global 100. Web: www.gtlaw.com Twitter: @GT_Law.